Patent Evaluation : US5 179093-: Schering Corp: Quinolinediones with activity against the herpetoviridae

Abstract

Novelty: Novel quinolinediones are disclosed which are claimed to be active against herpes group viruses. These compounds have potential for treatment of viral infections in mammals and such applications are claimed. The compounds may also prove useful against cytomegalovirus and Epstein-Barr virus. Advantages over known compounds include the early inhibition of viral replication.

Biology: The in vitro HSV activity was determined by reduction in galactosidase expression. For the specific compound IC₅₀ = 5 μg/ml. The in vivo efficacy was assessed using a guineapig model, following the method of Stanberry et al. (J. Infect. Dis. (1982) 146(3):397-404) and the specific compound (60 mg/kg sc) was found to have activity coefficients of 0.67 and 4.05 with respect to placebo and acyclovir.

Chemistry: The synthesis of thirty-one preferred derivatives and thirteen key intermediates are fully described. Twenty-one compounds are claimed including the specific example, (E,Z)-1-benzyl-3-benzylaminomethylene-quinolin-2,4-(1H)-dione.